Sugi Predict

Sugi Predict / Compounds / SCHEMBL2371293

SCHEMBL2371293

SCHEMBL2371293

O=C(O)c1cccc(-c2ccccc2Cl)c1

nearest known ligand 0.63

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ KMO O15229 1/20 0.61
▸ RXRA P19793 1/20 0.59
▸ RXRB P28702 1/20 0.59
▸ KAT6A Q92794 1/20 0.58
▸ CYP2A6 P11509 1/20 0.55
▸ FABP4 P15090 1/20 0.52
▸ PTGER1 P34995 3/20 0.51
▸ SCN9A Q15858 1/20 0.51
▸ CYP2C9 P11712 1/20 0.51
▸ NR1H4 Q96RI1 1/20 0.50
▸ GSK3B P49841 1/20 0.50
▸ NPC1 O15118 1/20 0.50
▸ CASP3 P42574 1/20 0.50
▸ RAB9A P51151 1/20 0.50
▸ SMN1; SMN2 Q16637 1/20 0.50
▸ SENP8 Q96LD8 1/20 0.50
▸ FOLH1 Q04609 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5841701 0.88 RXRA (0.57) KMORXRARXRBKAT6AFABP4
Benzoic Acid SCHEMBL10499109 0.87 CYP2A6 (0.68) KMORXRARXRBKAT6ACYP2A6
SCHEMBL30259065 0.87 KMO (0.73) KMORXRARXRBPTGER1CYP2C9
SCHEMBL2213546 0.87 KMO (0.73) KMORXRARXRBPTGER1CYP2C9
SCHEMBL6254589 0.86 RXRA (0.59) KMORXRARXRBPTGER1FOLH1
SCHEMBL5924860 0.85 CYP2A6 (0.54) KMORXRARXRBKAT6ACYP2A6
SCHEMBL15124553 0.85 CYP2A6 (0.54) KMORXRARXRBKAT6ACYP2A6
SCHEMBL382724 0.85 KMO (0.70) KMORXRARXRBPTGER1CYP2C9
SCHEMBL1707626 0.85 KMO (0.70) KMORXRARXRBPTGER1CYP2C9
SCHEMBL4200273 0.84 KAT6A (0.53) KAT6ACYP2A6SCN9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070088001-A1 Silinane compounds as cysteine protease inhibitors QUEST DIAGNOSTICS INVESTMENTS LLC 2007-04-19 — — US claimed
US-7109243-B2 Inhibitors of cathepsin S IRM LLC (BM) 2006-09-19 — — US claimed
US-12378224-B2 Heteroaryl compounds and their use as Mer inhibitors DONG-A SOCIO HOLDINGS CO., LTD. (KR) 2025-08-05 — — US disclosed
EP-3523292-B1 HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS DONG A SOCIO HOLDINGS CO LTD (KR) 2021-12-15 — — EP disclosed
US-20210371398-A1 HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS DONG A SOCIO HOLDINGS CO LTD (KR) 2021-12-02 — — US disclosed
CN-107835680-B Novel selective 11-beta-hydroxysteroid dehydrogenase type 1 帝斯曼知识产权资产管理有限公司 2021-11-09 — — CN disclosed
US-10913730-B2 Heteroaryl compounds and their use as Mer inhibitors DONG-A SOCIO HOLDINGS CO., LTD. (KR) 2021-02-09 — — US disclosed
US-10550097-B2 Selective 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors DSM IP ASSETS B.V. (NL) 2020-02-04 — — US disclosed
US-20190315716-A1 HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS DONG-A ST CO., LTD. (KR) 2019-10-17 — — US disclosed
EP-3324924-B1 NOVEL SELECTIVE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS DSM IP ASSETS BV (NL) 2019-08-21 — — EP disclosed
EP-3523292-A1 HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS Dong-A Socio Holdings Co., Ltd. (KR) 2019-08-14 — — EP disclosed
WO-2005074904-A2 SILINANE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS SCHERING AKTIENGESELLSCHAFT (DE) 2005-08-18 — — WO disclosed
WO-2004084842-A2 INHIBITORS OF CATHEPSIN S IRM LLC (BM) 2004-10-07 — — WO disclosed
US-20040198780-A1 Inhibitors of cathepsin S IRM LLC (BM) 2004-10-07 — — US disclosed
CN-1080257-C Guanidine derivatives as inhibitors of Na+/H+ exchange in cells FUJISAWA PHARMACEUTICAL CO (JP) 2002-03-06 — — CN disclosed
EP-0699185-B1 GUANIDINE DERIVATIVES AS INHIBITORS OF Na+ /H+ EXCHANGE IN CELLS FUJISAWA PHARMACEUTICAL CO (JP) 2001-09-05 — — EP disclosed
US-5824691-A CARDIOVASCULAR, CEREBROVASCULAR, RENAL DISEASES; SHOCK, ARTERIOSCLEROSIS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1998-10-20 — — US disclosed
CN-1123545-A Guanidine derivatives as inhibitors of Na+/H+ exchange in cells FUJISAWA PHARMACEUTICAL CO (JP) 1996-05-29 — — CN disclosed
EP-0699185-A1 GUANIDINE DERIVATIVES AS INHIBITORS OF Na+ /H+ EXCHANGE IN CELLS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1996-03-06 — — EP disclosed
WO-1994026709-A1 GUANIDINE DERIVATIVES AS INHIBITORS OF Na+/H+ EXCHANGE IN CELLS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1994-11-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10550097-B2 Selective 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors HSD11B1, HSD17B1, HSD3B1 KMO 2161/4885RXRA 2902/4885RXRB 2593/4885
US-10913730-B2 Heteroaryl compounds and their use as Mer inhibitors MERTK, RET, ERBB4 KMO 2157/4885RXRA 721/4885RXRB 684/4885
US-12378224-B2 Heteroaryl compounds and their use as Mer inhibitors MERTK, RET, ERBB2 KMO 2022/4885RXRA 670/4885RXRB 654/4885
US-20190315716-A1 HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS MERTK, RET, ERBB4 KMO 2157/4885RXRA 721/4885RXRB 684/4885
US-20210371398-A1 HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS MERTK, RET, ERBB2 KMO 2022/4885RXRA 670/4885RXRB 654/4885
US-20040198780-A1 Inhibitors of cathepsin S CTSS, CTSK, CTSE KMO 2287/4885RXRA 4851/4885RXRB 4839/4885
US-20070088001-A1 Silinane compounds as cysteine protease inhibitors CTSV, CTSB, CTSS KMO 1212/4885RXRA 4775/4885RXRB 4434/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.